DMRA - Galecto, Inc.

25.42
-0.480   -1.888%

Share volume: 109,046
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$25.90
-0.48
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 33%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.82%
1 Month
6.27%
3 Months
1.84%
6 Months
201.54%
1 Year
791.93%
2 Year
3,688.38%
Key data
Stock price
$25.42
P/E Ratio 
N/A
DAY RANGE
$25.16 - $26.92
EPS 
-$158.41
52 WEEK RANGE
$2.45 - $38.33
52 WEEK CHANGE
$776.55
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
60.303 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-28-2025
BETA 
1.72
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$268,562
AVERAGE 30 VOLUME 
$237,955
Company detail
CEO: Hans T. Schambye
Region: US
Website: galecto.com
Employees: 40
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Galecto, Inc. develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the. treatment of myelofibrosis. GB0139, an inhaled. inhibitor of galectin-3 that is in. Phase IIb clinical trials for severe fibrotic lung diseases.

Recent news